targeting her2 mutations in nsclc: what do we know?
Published 5 years ago • 722 plays • Length 5:49Download video MP4
Download video MP3
Similar videos
-
2:22
dr. pennell on the evolution of targeting her2 in lung cancer
-
10:30
expert highlights: targeting her2 and egfr in nsclc | tejas patil
-
17:15
her2 targeted therapy for treatment of nsclc
-
36:45
decoding her2 in nsclc: advances in biomarker testing and targeted therapies
-
3:30
osimertinib for uncommon egfr mutations in nsclc
-
3:26
lung cancer diagnosis: her2 mutation
-
4:07
her2- and met-mutation/amplification therapies
-
57:49
understanding her2 alterations in advanced non-squamous nsclc
-
6:09
mutation testing for nsclc
-
1:29
dr. lynch on targeting egfr mutation subtypes in lung cancer
-
2:54
her2 mutation positive nsclc
-
5:50
targeted therapy in egfr exon 20-mutant non–small cell lung cancer
-
58:30
the potential of her2-, her3-, and trop2-targeted therapies to address unmet needs in advanced nsclc
-
1:10
dr. bunn on data with trastuzumab deruxtecan in her2-mutant nsclc
-
3:29
burden of egfr exon 20 mutation in nsclc
-
3:10
targeting braf in nsclc
-
7:44
next-generation targeted therapies in non-small cell lung cancer
-
20:34
2021 west oncology | lung cancer | egfr mutation therapy resistance and adcs and trop2
-
5:10
sequencing egfr-targeted therapies in nsclc